ARTELO BIOSCIENCES, INC. (ARTL): Nasdaq/NYSE listing notice — Artelo Biosciences notified by Nasdaq of equity deficiency; $652K vs $2.5M minimum

ARTELO BIOSCIENCES, INC.

As of March 31, 2025, stockholders' equity was $652,000, below the $2.5M minimum required by Nasdaq Rule 5550(b)(1).
Company has 45 days (until July 7, 2025) to submit a compliance plan to Nasdaq.
If plan accepted, Nasdaq may grant up to 180 days (until Nov 18, 2025) to evidence compliance.
No immediate impact on listing; common stock continues trading on Nasdaq pending review.
Company evaluating options; no assurance that compliance plan will be accepted or delisting avoided.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

ARTELO BIOSCIENCES, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

May 22, 2025, Artelo Biosciences, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on The Nasdaq Capital Market to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing. On its Quarterly Report for the quarterly period ended March 31, 2025, the Company reported stockholders’ equity of $652,000, and, as a result, does not currently satisfy Nasdaq Listing Rule 5550(b)(1). Nasdaq’s letter has no immediate impact on the listing of t

View on SEC.gov

2 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

ARTELO BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0001640334-25-000935

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.